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Abstract
Background: In ovarian cancer, the reported rate of EGFR expression varies between 4-70% depending on
assessment method and data on patient outcome are conflicting. Methods: In this study we investigated EGFR
expression and its prognostic value in a cohort of 121 invasive ovarian carcinomas, using a novel antibody against
the intracellular domain of the receptor. We further evaluated an association between EGFR, the nuclear transporter
CRM1 as well as COX-2. Furthermore, we evaluated EGFR expression in ten ovarian cancer cell lines and incubated
cancer cells with Leptomycin B, a CRM1 specific inhibitor.
Results: We observed a membranous and cytoplasmic EGFR expression in 36.4% and 64% of ovarian carcinomas,
respectively. Membranous EGFR was an independent prognostic factor for poor overall survival in ovarian cancer
patients (HR 2.7, CI 1.1-6.4, p = 0.02) which was also found in the serous subtype (HR 4.6, CI 1.6-13.4, p = 0.004).
We further observed a significant association of EGFR with COX-2 and nuclear CRM1 expression (chi-square test for
trends, p = 0.006 and p = 0.013, respectively). In addition, combined membranous EGFR/COX-2 expression was
significantly related to unfavorable overall survival (HR 7.2, CI 2.3-22.1, p = 0.001).
In cell culture, we observed a suppression of EGFR protein levels after exposure to Leptomycin B in OVCAR-3 and
SKOV-3 cells.
Conclusions: Our results suggest that the EGFR/COX-2/CRM1 interaction might be involved in progression of
ovarian cancer and patient prognosis. Hence, it is an interesting anti-cancer target for a combination therapy.
Further studies will also be needed to investigate whether EGFR is also predictive for benefit from EGFR targeted
therapies.
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Background
Epithelial ovarian cancer, commonly diagnosed in an
advanced stage, has the highest mortality among gyne-
cological malignancies [1]. Surgical tumor debulking fol-
lowed by chemotherapy with a combination of
platinum-taxane as first line is the currently established
therapy. However, tumor relapse and development of
drug resistance are major problems in this disease, and
new molecular targeted therapies are urgently needed,
some of which have already entered clinical trials.
Epidermal growth factor receptor (EGFR) is one of
such attractive targets for anticancer therapy. Anti-
EGFR drugs, like monoclonal antibodies or small mole-
cule tyrosine kinase inhibitors have emerged as effective
agents in treating metastatic colorectal cancer and non-
small cell lung cancer. In contrast, clinical studies with
EGFR blocking drugs in advanced ovarian cancers have
shown only limited efficacy [2] but in the majority of
these trials, EGFR positivity was not analyzed as a selec-
tion criterion. To date, the exact frequency of EGFR
expression in ovarian cancer is not clear. The reported
range of EGFR expression varies between 4-70% and is
caused by different assessment methods and study
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copy numbers account approximately 15% [4-7], and
protein over-expression is detected in up to 60% [8].
The mechanisms of EGFR activation and particularly
the intracellular transactivation in ovarian cancer are
not yet fully elucidated. Transduction of EGFR signals is
mainly mediated by the RAS/MAPK- and PI3K/AKT-
pathway [2] and shuttle proteins confer signals from the
cytoplasm to the nucleus to transcription factors. CRM1
(chromosomal region maintenance/exportin 1) is an
important nuclear export receptor [9] which controls
shuttling of relevant tumor pathway elements like p53
[10], AKT1 [11], Her2 [12], and EGFR [13]. Further-
more, CRM1 is expressed in ovarian carcinomas, and
expression is associated with prognosis as well as COX-
2 regulation [14]. Therefore, we explored the possibility
of an interaction between EGFR, COX-2 and CRM1 in
ovarian cancer.
In this study, we investigate the EGFR protein expres-
sion using a novel antibody against the intracellular
domain of the receptor in a cohort of primary invasive
ovarian carcinomas as well as human ovarian cancer cell
lines. We further compare expression data with clinico-
pathological characteristics, patient survival as well as
CRM1 and COX-2 expression. To evaluate a possible
EGFR/CRM1 interaction, we incubate ovarian cancer
cells with Leptomycin B, a specific CRM1 inhibitor.
Methods
Study population
Invasive ovarian carcinomas of 121 patients who were
diagnosed at the Institute of Pathology Charité Univer-
sity Hospital Berlin (Germany) were included in this
study, which was conducted in the framework of the
tumor bank ovarian cancer (TOC) network http://www.
toc-network.de. All clinical data, including all surgical
procedures are documented in detail using a systematic
documentation tool [15]. These protocols have been
approved by the institutional review board of the Char-
ité Hospital. Formalin fixed and paraffin embedded
tumor tissue samples were evaluated on hematoxylin
and eosin sections. The stage of tumors was assessed
according to the International Federation of Gynecology
and Obstetrics (FIGO). Silverberg Grading System was
done by evaluation of architecture, nuclear polymorph-
ism and mitotic rate [16]. The median follow-up time of
the surviving patients was 38.1 months. Data on adju-
vant chemotherapy was known for 113 patients. In the
majority (94%), a platinum-based combination therapy
was administered.
Immunohistochemistry
Immunohistochemistry was performed on tissue micro-
arrays (TMAs) as described previously [17]. Briefly, slides
were deparaffinized and boiled in citrate buffer in a pres-
sure cooker for 5 minutes, incubated with the monoclo-
nal rabbit antibody directed against the internal domain
of EGFR (clone 5b7, Ventana Medical Systems, Tucson,
Arizona, USA). Further staining was carried out on the
BenchMark XT (Ventana Medical Systems, Tucson, AZ)
according to the manufactures’ instructions (protocol nr.
31). EGFR expression was scored as positive if tumor
cells displayed immunoreactivity in > 1% according to
the scoring system used in several previously published
studies [4,7,18]. Staining was evaluated by an experienced
pathologist (M.S.) who was blinded towards patient char-
acteristics and outcome. Negative control was performed
by omitting the primary antibody. The antibody specifity
was evaluated by Western blotting. In addition, immuno-
histochemical data on CRM1 and COX-2 expression was
available for 60 and 62 ovarian cancer specimens from
previous studies [14,19].
Cell culture, inhibitor and immunoblotting
The human ovarian cancer cell lines (OVCAR-3, SKOV-
3, ES-2, OAW42, CAOV-3, A27/80, FU-OV-1, EFO-21,
EFO-27, Mdah2774) and immortalized normal human
ovarian surface epithelial (HOSE) cells investigated in
this study have recently been described [14,17]. Cells
were incubated with Leptomycin B (LMB), a specific
CRM1 inhibitor (L2913; Sigma Chemical Company) for
a maximum of 72 hours at different concentrations (2.5,
and 5 ng/ml) as reported previously [14].
For protein analysis, cells were lysed in 100 μlo f6 2 . 5
mM Tris-HCl (pH 6.8) containing 2% sodium dodecyl
sulfate, 10% glycerol, 50 mM DTT and 0.1% bromophe-
nole blue. 100 μg protein/sample were separated on a
10% polyacrylamide gel, blotted onto nitrocellulose
membranes (Schleicher&Schuell, Dassel, Germany),
washed in PBS, and blocked in buffer (1 × PBS, 0.1%
Tween-20, 5% i-block (Tropix, Bedford, MA, USA)) for
one hour at room temperature. Membranes were probed
with the monoclonal anti-EGFR antibody (clone 5b7,
Ventana Medical Systems, Tucson, Arizona, USA) over-
night at 4°C, diluted 1:1000 in blocking buffer, and fol-
lowed by incubation with alkaline phosphatase-
conjugated goat anti-rabbit secondary antibody (Tropix).
Bands were visualized using the CDP star RTU lumines-
cence system (Tropix).
Statistics
For statistical analysis, the SPSS software package (IBM
SPSS statistics version 19.0) was used. Association of
EGFR with clinico-pathological parameters was assessed
by the two-sided Fisher’s exact test or a chi-square test
for trends as indicated. Spearman’s correlation was used
to evaluate an association between CRM1 and COX-2.
The univariate survival analysis was done using the
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with the log rank test. Cox proportional hazard models
were fitted in order to calculate hazard ratios and to
carry out multivariate survival analyses. In general, p-
values < 0.05 were considered significant.
Results
Clinico-pathological characteristics of ovarian cancer
patients
Primary invasive ovarian carcinomas of 121 women were
investigated for EGFR expression. Mean patient age at
the time of surgery was 57 years, ranging from 33 to 80.
The main histological subtype of the invasive carcino-
mas was serous cancer (66.1%). The group of non-ser-
ous cancer (24%) consists of the endometrioid subtype
(n = 12, 9.9%), transitional cell type (n = 8, 6.6%), muci-
nous type (n = 5, 4.1%), and clear cell carcinomas (n =
4, 3.3%). Characteristics of the study population are
given in Table 1.
EGFR expression in ovarian carcinomas
Immunohistochemical analysis was performed on 121
ovarian carcinomas (Figure 1). We observed a membra-
nous as well as a cytoplasmic EGFR expression. There-
fore both staining patterns were evaluated separately to
identify a possible cell specific localisation of EGFR and
to evaluate an association of a specific pattern with
prognostic pathological parameters. Membrane staining
is defined as any immunoreaction in part of the cell
membrane (complete or incomplete), while the cytoplas-
mic immunoreaction is confined to the intracellular
compartment. A positive membranous staining was
found in 36.4% (44 out of 121) and a cytoplasmic reac-
tion in 67% (81 out of 121). Both expression patterns
were significantly associated (chi-square test for trends,
p = 0.003). No associations between membranous or
cytoplasmic EGFR expression, and clinico-pathological
parameters as listed in Table 1 were found.
Membranous EGFR expression is related to CRM1 and
COX-2 expression
To identify an association of EGFR with CRM1 and
COX-2, we compared EGFR protein expression with
data on CRM1 and COX-2 expression which was inves-
tigated previously [14]. The nuclear export protein
CRM1 is expressed both in the nucleus and cytoplasm
of ovarian carcinomas as described recently [14]. Here,
we found that membranous EGFR expression is asso-
ciated with nuclear CRM1 expression (chi-square test
for trends, p = 0.013). Further, membranous EGFR
expression is associated with COX-2 expression (chi-
square test for trends, p = 0.006). CRM1 and COX-2
expression correlated with each other (spearman corre-
lation coefficient 0.371, p = 0.001), as described pre-
viously [14].
Membranous EGFR expression is an independent
prognostic factor for overall survival
In univariate Kaplan-Meier survival analysis and logistic
regression analysis (Table 2), high tumor grade,
Table 1 Characteristics of 121 patients with invasive
ovarian carcinomas
Parameter All cases (%)
Age at surgery (years)
< 60 73 (60.3)
≥ 60 48 (39.7)
Histological type
serous 80 (66.1)
non-serous 29 (24.0)
undifferentiated 12 (9.9)
FIGO stage
I 18 (14.9)
II 10 (8.3)
III 84 (69.4)
IV 9 (7.4)
Tumor stage
pT1 21 (17.3)
pT2 12 (10.0)
pT3 88 (72.7)
Nodal stage (n = 96)
pN0 46 (47.9)
pN1 50 (52.1)
Tumor grade (Silverberg)
G1 19 (15.7)
G2 50 (41.3)
G3 52 (43.0)
Intraoperative residual tumor (n = 88)
residual tumor < 2 cm 78 (88.6)
residual tumor ≥ 2 cm 10 (11.4)
Chemotherapy (n = 113)
Platinum-based 106 (93.8)
non-platinum 3 (2.7)
no chemotherapy 4 (3.5)
Figure 1 Immunohistochemical analysis of EGFR.A :
Membranous and weak cytoplasmic expression in a high-grade
serous ovarian carcinoma. B: Pure membranous expression in a
high-grade serous carcinoma.
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are significantly associated with unfavourable patient
overall survival. FIGO stage, tumor and nodal stage did
not reach prognostic significance in our cohort. Further,
membranous EGFR expression was significantly asso-
ciated with shorter overall survival (log rank, p = 0.002;
Figure 2A). In a multivariate Cox regression analysis
adjusted for other prognostic factors, membranous
EGFR expression was confirmed as an independent
prognostic factor for overall survival in ovarian cancer
patients (Table 3). For cytoplasmic EGFR expression, no
significant differences were found. In a subgroup analy-
sis (Table 4), membranous EGFR expression was
observed in 25 out of 80 (31.3%) serous ovarian carcino-
mas and significantly related to poor overall survival in
this cancer subtype (log rank, p < 0.001; Figure 2B),
which was confirmed in a multivariate analysis (HR 4.6,
CI 1.6-13.4, p = 0.004). No association between mem-
branous EGFR and non-serous cancer type was observed
(log rank, p = 0.72). Regarding the progression-free sur-
vival, no significant differences for membranous or cyto-
plasmic EGFR expression (log rank, p = 0.58 and p =
0.85, resp.) were found.
Since expression data of membranous EGFR (mEGFR)
was strongly related to CRM1 and COX-2 expression
levels, we aimed to evaluate the impact of a combination
of these molecules on patient survival. Here, we
observed that nuclear CRM1 (Figure 3A) as well as
COX-2 (Figure 3B) expression is related to poor overall
survival in ovarian carcinomas (log rank, p = 0.019; n =
60 and p < 0.001; n = 62), which is in line with previous
findings [19]. Combined expression of mEGFR/COX-2
was significantly associated with unfavorable overall sur-
vival in all carcinomas (p < 0.001) and the serous sub-
type (p = 0.006). In addition, combined mEGFR/COX-2
expression was an independent prognostic factor in
multivariate analysis (HR 16.5, CI 2.6-104.7, p = 0.003)
adjusted for other prognostic factors (Table 5). Com-
bined mEGFR/CRM1 showed a trend for unfavorable
overall survival in all carcinomas (HR 3.3, CI 0.9-11.7, p
= 0.06). The combination of EGFR/COX-2/CRM1 had
no significant impact on overall survival (HR 3.0, CI 0.9-
10.6, p = 0.8).
Expression of EGFR in ovarian cancer cells
We investigated the EGFR protein expression in ten
ovarian cancer cell lines as well as in immortalized
human ovarian surface epithelium cells (HOSE) by Wes-
tern Blot. We observed high EGFR levels in several
ovarian cancer cells in particular in OVCAR-3, SKOV-3,
ES-2, OAW-42, CaOV-3, and EFO-27 cells. In contrast,
A27/80 and Mdah2774 showed no expression of EGFR.
The FU-OV-1 and EFO-21 cancer cells as well as HOSE
cells showed only weak expression (Figure 4A).
Suppression of EGFR after exposure to Leptomycin B
(LMB)
Due to the association of CRM1 and EGFR protein
expression in ovarian carcinomas, we aimed to evaluate
the interaction of both in a cell culture model. For this
purpose, we treated two ovarian cancer cell lines with
Leptomycin B (LMB), which specific inactivates CRM1
and thus the nuclear export of proteins. Incubation of
Table 2 Univariate analysis: factors predicting overall
survival
Parameter n (%) Overall survival
p-value
(log rank)
HR (CI),
p-value
Membranous EGFR 121 (100) 0.002 2.8 (1.4-5.6),
0.004
positive 44 (36.4)
negative 77 (63.6)
Cytoplasmic EGFR 121 (100) 0.79 0.9 (0.4-1.8),
0.79
positive 81 (66.9)
negative 40 (33.1)
Age at surgery (years) 121 (100) 0.003 2.8 (1.3-5.7),
0.004
< 60 73 (60.3)
≥ 60 48 (39.7)
Histological type 121 (100) 0.71 1.1 (0.7-1.9),
0.68
serous 80 (66.1)
non-serous 29 (24.0)
undifferentiated 12 (9.9)
FIGO stage 121 (100) 0.44 1.5 (0.9-2.5),
0.13
I 18 (14.9)
II 10 (8.3)
III 84 (69.4)
IV 9 (7.4)
Tumor stage 121 (100) 0.14 1.6 (0.9-2.9),
0.08
pT1 21 (17.3)
pT2 12 (10.0)
pT3 88 (72.7)
Nodal stage 96 (100) 0.05 2.7 (0.9-7.8),
0.06
pN0 46 (47.9)
pN1 50 (52.1)
Tumor grade 121 (100) 0.035 2.0 (1.1-3.5),
0.013
G1 19 (15.7)
G2 50 (41.3)
G3 52 (43.0)
Intraoperative residual
tumor
88 (100) 0.0001 5.0 (1.9-13.0),
0.001
residual tumor < 2 cm 78 (88.6)
residual tumor ≥ 2 cm 10 (11.4)
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tomycin B revealed a significant suppression of EGFR
protein levels (Figure 4B).
Discussion
In this study, we used a novel antibody to assess the
E G F Rp r o t e i ne x p r e s s i o ni np r i m a r yi n v a s i v eo v a r i a n
carcinomas. We observed a membranous EGFR expres-
sion in 36.4% which was an independent predictor of
factor for poor overall survival in ovarian cancer
patients.
There are several reports on EGFR as an adverse prog-
nostic indicator in different tumor types. In ovarian carci-
nomas different results exist concerning EGFR
expression and disease outcome. Psyrri et al. reported on
an association of EGFR protein expression with poor dis-
ease-free and overall survival in a cohort of 81 advanced
ovarian carcinomas (FIGO III/IV) with intraoperative
residual disease more than 2 cm in 75% of cases [20]. In
another cohort of 379 serous ovarian carcinomas amplifi-
cation and membranous protein over-expression of
EGFR were also related to poor overall survival [5]. In
contrast, de Graeff et al. did not observe any association
between membrane EGFR expression assessed by immu-
nostaining and disease outcome in a prospective study of
232 ovarian carcinomas [21]. Similarly, Nielsen et al.
reported on an EGFR over-expression in 62% of 783
ovarian cancer patients which had no prognostic impact
[8]. As reviewed in a meta-analysis of de Graeff et al.,
reported EGFR expression is ranging from 6 to up 70% in
ovarian carcinomas [3]. The variability among the studies
is most likely caused by different assessment methods
and antibodies, scoring systems, standardization
approaches, and different study cohorts. In this project,
we used an antibody which detects the intracellular
domain of the receptor, whereas previous studies applied
an antibody detecting the external receptor domain
[4,5,7].
We found no association with standard clinico-patho-
logical factors which is in line with findings from other
authors [20]. In contrast, other reports showed an asso-
ciation of EGFR expression with higher patient age, lar-
ger residual tumor size [5], and high-grade serous
carcinomas [5,22], while de Graeff et al. found that
over-expression of EGFR was more frequent in non-ser-
ous tumors [21].
In this study, we demonstrate for the first time an
association between EGFR and the nuclear export pro-
tein CRM1 in ovarian cancer tissue. CRM1 is responsi-
ble for nucleo-cytoplasmic shuttling of mRNAs and
proteins of cancer related molecules including ErbB2
[12]. Due to the in vivo findings, we further aimed to
investigate the interaction of EGFR and CRM1 in a cell
Figure 2 Univariate survival analyses for membranous EGFR. A: In Kaplan-Meier analysis, membranous EGFR is associated with poor overall
survival in all ovarian carcinomas. B: Membranous EGFR is associated with poor overall survival in the subgroup of serous ovarian carcinomas.
Table 3 Multivariate logistic regression analysis
Characteristic Hazard Ratio (95% CI) p-value
Membranous EGFR (pos. vs. neg.) 2.7 (1.1-6.4) 0.02
Age 1.1 (1.0-1.1) 0.01
FIGO stage (I+II vs. III+IV) 3.1 (0.4-23.8) 0.3
Tumor grade (G1 vs. G2+3) 1.5 (0.2-11.6) 0.7
Residual tumor (< 2 vs. ≥ 2 cm) 4.0 (1.4-11.1) 0.008
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levels after exposure with Leptomycin B in ovarian can-
cer cells suggest a role of CRM1 in the intracellular
transactivation of EGFR. In contrast, Lo et al. detected
increased nuclear EGFR levels following LMB incuba-
tion for a maximum of 4 hours in A431 human epider-
moid carcinoma cells [13]. The intracellular transit and
abidance in specific cell compartments of EGFR may
depend on the cell type, stimulation with growth factors,
and duration of CRM1 inhibition.
In our analysis, we also observed an association
between membranous EGFR and COX-2. Several studies
have reported a crosstalk between EGFR and COX-2.
Xu et al. reported that EGF-mediated stimulation of
EGFR in human glioma cell lines induces expression of
both COX-2 mRNA and protein [23]. As reviewed by
Dannenberg et al., EGFR signaling may lead to AP-1-
mediated induction of COX-2 transcription via
increased MAPK activity. In turn, enhanced prostanoid
production driven by COX-2 can activate EGFR signal-
ing [24]. Moreover, Jeong KJ and colleagues demon-
strated that lysophosphatidic acid receptor, LPA2 and
Gi/Src transactivation to EGFR are responsible for
COX-2 expression in ovarian cancer cells [25]. The
interaction of EGFR and COX-2 might be relevant for
combined treatment strategies. Gupta et al. used genetic
and pharmacological agents for inactivation of four
genes, as the EGFR ligand epiregulin, COX-2, and two
metalloproteinases (MMP1 and 2) and demonstrated a
repression of primary tumor growth, tumor cell intra-
und extravasation as well as metastatic outgrowth [26].
So far, only few studies have explored the possibility of
an interaction of both molecules in ovarian cancer. In
two immunohistochemical studies no association was
found [27].
These data and our findings show a possible interac-
tion of EGFR, COX-2, and CRM1 in ovarian cancer. In
our previous studies, COX-2 was identified as an inde-
pendent prognostic factor for poor overall survival in
ovarian cancer patients [19] and related to CRM1 in
vitro and in vivo [14]. The prognostic impact as well as
its correlation and regulation of each other suggest an
important role in the progression of ovarian cancer that
has to be confirmed in further studies. Moreover, this
crosstalk is interesting for combination therapies in
anti-cancer treatment. So far, the application of anti-
EGFR therapy in ovarian cancer has been shown only
limited efficacy; therefore further studies will be needed
Table 4 Univariate survival analysis for the complete study cohort and the serous subtype
characteristic all histological subtypes serous subtype
n Hazard ratio (CI 95%) p-value n Hazard ratio (CI 95%) p-value
mEGFR 120 2.8 (1.4-5.6) 0.004 77 5.8 (2.4-14.1) < 0.001
CRM1 60 3.9 (1.1-14.0) 0.031 39 3.4 (0.7-17.0) 0.13
COX-2 62 4.9 (1.8-12.7) 0.001 41 4.8 (1.3-17.8) 0.02
mEGFR+COX-2 62 7.2 (2.3-22.1) 0.001 41 5.9 (1.5-23.7) 0.013
Figure 3 Univariate survival analyses for CRM1 and COX-2. A-B: CRM1 and COX-2 expression is related to unfavorable overall survival in
ovarian cancer patients.
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dictive for benefit from EGFR targeted therapies.
Conclusions
In this study, we show that membranous EGFR expres-
sion is an independent prognostic factor for poor overall
survival in ovarian cancer patients. We further demon-
strate a significant association of EGFR with COX-2 and
nuclear CRM1 expression. In addition, combined mem-
branous EGFR/COX-2 expression is significantly related
to unfavorable overall survival. In cell culture, we show
a suppression of EGFR protein levels after exposure to
the CRM1 inhibitor Leptomycin B in OVCAR-3 and
SKOV-3 cells. Our results suggest that the EGFR/COX-
2/CRM1 interaction might be involved in progression of
ovarian cancer and patient prognosis. Hence, it is an
interesting anti-cancer target for a combination therapy.
Further studies will also be needed to investigate
whether EGFR is also predictive for benefit from EGFR
targeted therapies.
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